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The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies.
Scheduling and sequencing remain key issues in the design of VDA–chemotherapy combination treatments. This study examined the
antitumour activity of ZD6126, a microtubule destabilising VDA, in combination with paclitaxel (PTX), a microtubule-stabilising
cytotoxic drug, and the influence of schedule and sequence on the efficacy of the combination. Nude mice bearing MDA-MB-435
xenografts received weekly cycles of ZD6126 (200mgkg
 1 i.p.) administered at different times before or after PTX (10, 20, and
40mgkg
 1 i.v.). ZD6126 given 2 or 24h after PTX showed no significant benefit, a result that was attributed to a protective effect of
PTX against ZD6126-induced vascular damage and tumour necrosis, a hallmark of VDA activity. Paclitaxel counteracting activity was
reduced by distancing drug administrations, and ZD6126 given 72h after PTX potentiated the VDA’s antitumour activity. Schedules
with ZD6126 given before PTX improved therapeutic activity, which was paralleled by a VDA-induced increase in cell proliferation in
the viable tumour tissue. Paclitaxel given 72h after ZD6126 yielded the best response (50% tumours regressing). A single treatment
with ZD6126 followed by weekly administration of PTX was sufficient to achieve a similar response (57% remissions). These findings
show that schedule, sequence and timing are crucial in determining the antitumour efficacy of PTX in combination with ZD6126.
Induction of tumour necrosis and increased proliferation in the remaining viable tumour tissue could be exploited as readouts to
optimise schedules and maximise therapeutic efficacy.
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The tumour vasculature is an established target for the therapy of
solid tumours. Agents designed to prevent the formation of new
tumour vessels (antiangiogenic therapy) or to damage already
formed vessels (vascular targeting/disrupting therapy) have been
developed and have shown efficacy in preclinical models, and
recently, in clinical studies (Taraboletti and Margosio, 2001;
Thorpe, 2004; Ferrara and Kerbel, 2005; Tozer et al, 2005; Chaplin
et al, 2006).
The concept of vascular disruption in cancer treatment is based
on the differences between vessels of the tumour microenviron-
ment and those of normal tissues: the former are immature, highly
permeable, and chaotic with heterogeneous blood flow rates,
features that predispose them to the selective action of vascular
disrupting agents (VDAs) (reviewed in Thorpe, 2004; Tozer et al,
2005). These compounds induce morphologic alterations of the
endothelial cells in tumour vessels (Davis et al, 2002; Micheletti
et al, 2003) that trigger a cascade of events ultimately leading to
vessel shutdown and tumour necrosis (reviewed in Thorpe, 2004;
Tozer et al, 2005). Initial events, detected as early as 5–25min
following treatment, include increased permeability to macro-
molecules, vasoconstriction of tumour supplying arterioles,
reduction of blood flow and consequent hypoxia (Horsman and
Murata, 2003; Skliarenko et al, 2006). Thereafter, platelet activa-
tion, coagulation, vessel occlusion, recruitment of inflammatory
cells, and direct effects on vascular remodelling may occur,
leading to necrosis of the tumour tissue (Blakey et al, 2002;
Davis et al, 2002; Goertz et al, 2002; Micheletti et al, 2003;
Robinson et al, 2003). Typically, the final effect of VDAs on
tumours is the induction of massive central necrosis (after 24h),
with a rim of viable, proliferating cells remaining at the tumour
periphery. These viable tumour cells can rapidly repopulate the
tumour, which is then able to resume its growth, unless treatment
with the VDA is repeated or the VDA is combined with other types
of treatments.
Vascular disrupting compounds include small molecule tubulin-
binding agents, flavonoids (DMXAA and FAA), antagonists of
junctional proteins, and compounds that target proteins expressed
exclusively on the tumour vasculature and are usually used to
deliver bioactive molecules (Thorpe, 2004; Neri and Bicknell, 2005;
Tozer et al, 2005; Chaplin et al, 2006). Several tubulin-binding
VDAs (CA4P, ZD6126, AVE8062, Oxi-4503, MN-029, ABT-751, and
TZT-1027) have been developed and are undergoing preclinical
testing and clinical investigation. Among these, ZD6126 is a
synthetic water-soluble phosphate prodrug, which is rapidly
converted in vivo into the tubulin-binding ZD6126 phenol, a
microtubule destabilising colchicine analogue. The effects of the
compound on endothelial cells in vitro and on neo-vessels in vivo
are well documented (Blakey et al, 2002; Davis et al, 2002;
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sMicheletti et al, 2003), as is its ability to induce tumour necrosis
in experimental models (Blakey et al, 2002; Siemann and
Rojiani, 2002b; McCarty et al, 2004; Taraboletti et al, 2005;
Skliarenko et al, 2006).
Preclinical studies have highlighted the potential of using VDAs
in combination with conventional therapies, and clinical trials of
VDAs in combination regimens are currently underway (reviewed
in Chaplin et al, 2006). The benefit sought from such combinations
is mainly a complementary action between the two agents, with
the VDA acting primarily on the tumour vasculature and the
chemotherapy or radiotherapy mainly affecting proliferating
tumour cells. Moreover, clinical studies have indicated that the
toxicity profile of VDAs differs from that of conventional
chemotherapy, thus ruling out additive toxicity as a major
limitation of the combination. In preclinical studies, ZD6126 has
been reported to synergise with radiotherapy (Siemann and
Horsman, 2002; Siemann and Rojiani, 2002b; Horsman and
Murata, 2003; Wachsberger et al, 2005), chemotherapy (Blakey
et al, 2002; Siemann and Rojiani, 2002a; Goto et al, 2004),
inhibitors of angiogenesis (Siemann and Shi, 2004), and molecular-
targeted agents (Bozec et al, 2006).
While confirming the potential benefits of combination treat-
ments, preclinical studies have also underscored the importance of
dose, schedule, and sequence to optimise the putative additive
effects of combination approaches and to prevent possible negative
inhibition (Siemann and Rojiani, 2002b; Wachsberger et al, 2005).
We have reported previously a potential interfering effect when
combining VDAs with chemotherapy agents sharing the same
molecular target (tubulin). Taxanes (e.g., paclitaxel (PTX)) are
microtubule-stabilising agents, and therefore possess an opposite
effect to that of microtubule-destabilising VDAs. In addition, both
VDAs and taxanes can act on endothelial cells: by affecting
microtubule dynamic instability, taxanes inhibit endothelial cell
functions relevant to angiogenesis, thereby acting as antiangio-
genic compounds (Belotti et al, 1996). We have shown that PTX,
given shortly before ZD6126, protected endothelial cells from the
activity of the VDA, ultimately preventing its ability to induce
vessel occlusion and tumour necrosis in experimental models
(Taraboletti et al, 2005). We therefore designed the present study
to investigate in vivo the antitumour activity of ZD6126 in
combination with PTX on a human xenograft model, as well as to
explore the influence of the drug schedule and sequence on
the efficacy of the ZD6126/PTX combination. Tumour responses to
the VDA were used as end points to guide the design of the
combination with PTX, an approach, which allowed us to optimise
conditions for combination regimens.
MATERIALS AND METHODS
Tumour cells
The human MDA-MB-435 cancer cell line (Price et al, 1990;
Sellappan et al, 2004) was obtained from the NCI-DCTD Tumour
Repository, Frederick, MD, USA. Cells were cultured in DMEM
supplemented with 10% fetal bovine serum.
Animals
Female NCr-nu/nu mice were obtained from the animal produc-
tion colony of the National Cancer Institute, Frederick Cancer
Research and Development Center (Frederick, MD, USA).
(Procedures involving animals and their care were conducted in
conformity with institutional guidelines, which are in compliance
with national (DL no. 116, GU, Suppl. 40, February 18, 1992;
Circolare no. 8, GU, July, 1994) and international laws and
policies (EEC Council Directive 86/609, OJ L 358. 1, December 12,
1987; Standards for the Care and Use of Laboratory Animals,
United States National Research Council, Statement of Compliance
A5023-01, November 6, 1998.) Mice were used when 8–10 weeks
of age (mean body weight¼23±2g). Nude mice were housed in
filtered-air laminar flow cabinets and manipulated following
aseptic procedures.
Drug preparation
ZD6126 (MW 437Da), provided by AstraZeneca, Alderley Park,
Macclesfiled, UK, was dissolved in PBS with 0.5% Na2CO3 and
administered i.p. Paclitaxel (PTX, kindly provided by Indena
S.p.A., Milan, Italy) was dissolved in 50% Cremophor EL (Sigma,
Milan, Italy) and 50% ethanol and further diluted with saline
immediately before i.v. administration.
Antitumour activity
MDA-MB-435 cells (5 10
6) were implanted s.c. in the flanks of
nude mice (see explanation in section on ‘Animals’). Tumour
growth was monitored two times a week by measuring tumour size
with calipers, and estimating tumour weight, in grams, calculated
as ((length width
2)/2). Treatment started when tumours reached
the size of approximately 450mg, since preliminary results
indicated that the activity of VDA is optimal on established
tumours (data not shown). Animals were randomised on the basis
of tumour weight and subjected to treatment (each group
consisted of 6–10 mice). Mice received ZD6126 (i.p.) and PTX
(i.v.) at the doses, schedules, and sequence detailed in the Results
section. Control mice received the corresponding vehicle. Experi-
ments were concluded when tumours reached a median weight of
2±0.5g or 4–5 weeks after the last treatment.
Tumour growth was expressed as relative tumour weight
RTW¼Wt/Wo, where Wt is the tumour weight at any day of
measurement and Wo was the tumour weight at the start of
treatment. Efficacy of the treatment was expressed as %T/C
((median RTW of treated tumours/median RTW of control
tumours) 100). Treatment was considered active when optimal
%T/C (the lowest %T/C value for each treatment condition) was
lower than 40%. Specific growth delay (SGD) was calculated as
((DT treated – DT control)/DT control), where DT (doubling time)
is the time (in days) necessary to double the initial tumour
weight (namely to reach a RTW¼2). Specific growth delay
was considered active when 41. Complete regression was
defined as fully regressed tumours, yet undetectable by palpa-
tion at the end of the experiment. Statistical differences among
groups were evaluated by ANOVA followed by Bonferroni/Dunn
post hoc test.
Analysis of tumour necrosis, mitosis, and proliferation
Nude mice were transplanted s.c. with MDA-MB-435 cells as
described above. For the evaluation of tumour necrosis, mice
bearing tumours of approximately 450mg were randomised and
treated with vehicle or PTX (20mgkg
 1, i.v.), followed 2, 24, 72h,
and 1 week later by ZD6126 (200mgkg
 1, i.p.) (n¼5 mice per
group). Tumours were then removed 24h after treatment with
ZD6126, cut sagittally along the midline, fixed in formalin and
processed for histological analysis. Five-micrometer sections were
cut and stained with haematoxylin and eosin (H&E) following
standard procedures. Images of the whole sagittal H&E-stained
tumour sections were captured using a Nikon Super Coolscan 4000
ED film scanner (Nikon, Tokyo, Japan). Necrosis was analysed by
computerised image analysis (Image Pro-Plus 4.5, Media Cyber-
netics, Silver Spring, MD, USA), exploiting the difference in
staining intensity between vital and necrotic tissue (Taraboletti
et al, 2005). Area of necrosis was expressed as the percentage of
total tumour area. Presence of necrosis was also confirmed by
histopathological analysis.
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MDA-MB-435 tumours were collected 24h after administra-
tion of ZD6126 (200mgkg
 1, i.p.) or vehicle (n¼5 mice per
group), fixed and stained with H&E as above or immunostained
for Ki-67. Antibodies against Ki-67 (clone MM1, Ventana Medical
Systems, Tucson, AZ, USA) were used according to the manu-
facturers’ specifications. Negative control included omission of
the primary antibody and incubation with non-immune
serum. Background immunostaining was found to be negligible
when non-immune serum was substituted for specific antiserum.
Immunostaining was visualised by the avidin–biotin–peroxidase
complex method using the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA, USA) with 2,20-diaminobenzidine
as a substrate. Haematoxylin was used to counterstain the nuclei
of the specimens after immunostaining. Positively stained cells
were identified by the presence of a brown nuclear precipitate.
Negative cells were identified by the absence of precipitate and
only blue counterstain.
For each H&E- and Ki-67-stained section, five random non-
overlapping fields at a magnification of  400 (high-power
field (HPF)) in the viable areas of tumours were captured with
an Olympus Camedia C-3030 Zoom digital camera (Olympus,
Tokyo, Japan). Images were analysed with Image Pro-Plus. Mitotic
figures and total cell number were counted in five HPFs/tumours,
and the mitotic index was expressed as the number of mitoses
per 500 cells. The proliferation index was expressed as the
percentage of Ki-67-positive nuclei per total number of cells.
Statistical differences among groups were evaluated by ANOVA
followed by Bonferroni/Dunn post hoc test (comparison between
more than two groups) or Mann–Whitney U-test (comparison
between two groups).
RESULTS
Paclitaxel administered before ZD6126 prevents its
vascular disrupting activity
We first evaluated the effect of combination regimens with ZD6126
given after PTX. The rationale for this schedule was that the
vascular effect of the VDA would cause ‘trapping’ of the already
present cytotoxic drug within the tumour, and, at the same time,
that the possible VDA-induced impairment of PTX distribution in
the tumour would be avoided (Chaplin et al, 2006).
Figure 1 shows the antitumour activity of a combination regimen
with ZD6126 given shortly (2h) after PTX on the growth of
established MDA-MB-435 xenografts. Paclitaxel alone, given at 10,
20, and 40mgkg
 1, caused a dose-dependent inhibition of tumour
growth, with a %T/C of 55.5, 38.9, and 20.2, respectively (Figure 1).
ZD6126 alone (200mgkg
 1) modestly affected the tumour growth
with a %T/C ranging from 68.7 to 76.7. The administration of
ZD6126 2h after PTX treatment showed no significant additional
benefit compared with PTX alone. This was evident at all doses of
PTX (%T/C¼59.0, 49.9, and 20.6, respectively, for the combination
with PTX at 10, 20, and 40mgkg
 1).
The lack of potentiating effect of this combination schedule is in
agreement with the reported interference between the two agents,
which have an opposite effect on the same target, that is,
microtubules (Taraboletti et al, 2005). We have previously shown
that PTX, which stabilises microtubules, reversibly protects
endothelial cells from the microtubule destabilising activity of
ZD6126, thereby preventing microtubule depolymerisation, vessel
shutdown, and tumour necrosis induced by the VDA (Taraboletti
et al, 2005). This protective effect was due to the opposite actions
of the two drugs on microtubules (Taraboletti et al, 2005).
A similar combination schedule of ZD6126 with a tubulin-binding
compound having microtubule destabilising properties, namely,
vincristine, was more effective in damaging endothelial cells than
the single agents (Taraboletti et al, 2005) and did not interfere with
ZD6126-induced tumour necrosis (not shown), thus confirming
that interference occurred specifically with PTX.
Since prevention of VDA activity by PTX was reversible
(Taraboletti et al, 2005), we hypothesised that by increasing the
time interval between the administrations of the two agents, the
interference between the two drugs would be overcome, and
eventually the antineoplastic activity of the combination improved.
To determine the timing conditions that minimise the protective
effect of PTX, we used as readout the analysis of central tumour
necrosis caused by ZD6126 (Taraboletti et al, 2005). In MDA-MB-
435 tumours, a single injection of ZD6126 alone caused massive
central necrosis of the tumour mass, evident 24h after treatment
(6.7 times greater than vehicle), whereas PTX alone had no effect
(Figure 2A). ZD6126-induced necrosis was prevented by adminis-
tering PTX (20mgkg
 1) 2 or 24h before the VDA (Figure 2A).
However, when the interval between PTX and ZD6126 adminis-
tration was lengthened, the protective effect of PTX was reduced
(72h) or no longer observed (1 week), and ZD6126 was again able
to induce the typical pattern of massive central necrosis
surrounded by the rim of viable cells at the tumour periphery
(Figure 2A, inset). This finding indicated that drug interference
might be overcome by allowing a time interval of at least 72h
between administrations of PTX and the VDA. Indeed, ZD6126
given 24h after PTX showed no significant benefit compared to
administration of the single agents (Figure 2B), whereas ZD6126
given 72h after PTX resulted in greater antitumour activity than
each single agent, generating an increase in doubling time (10.1,
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Figure 1 Effect of paclitaxel (PTX) given 2h before the administration of ZD6126. Mice bearing MDA-MB-435 xenografts (approximately 450mg) were
treated weekly with PTX, ZD6126 or the combination for four courses. Paclitaxel was administered i.v. at the dose of (A)1 0m gk g
 1,( B)2 0m gk g
 1, and
(C)4 0m gk g
 1 followed, after 2h, by ZD6126 (200mgkg
 1 i.p.). Mice not receiving drugs were treated with the corresponding vehicle at the same times.
n¼7–8. Black (PTX) and white (ZD6126) arrowheads indicate treatments.
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combination, respectively) and SGD (1.0 and 4.5 for PTX and the
combination, respectively (Figure 2C). One out of six mice in this
group was tumour free at the end of the study.
ZD6126 administered before paclitaxel potentiates
antitumour activity
In a second set of experiments, we investigated the inverse
combination schedule, namely giving the ZD6126 before PTX. The
rationale underlying this schedule was that VDA-treated tumours
rapidly regrow from the rim of residual viable cells at the tumour
periphery that shows prominent proliferative activity (Thorpe,
2004; Tozer et al, 2005). Highly proliferating cells are ideal targets
for cytotoxic drugs, a premise that underpins the hypothesis that
pre-administration of the VDA might generate favourable condi-
tions for the activity of chemotherapy. ZD6126-induced increase in
proliferative activity at the tumour periphery was measured as the
expression of Ki-67, a marker of cell proliferation, and the mitotic
index in the periphery of MDA-MB-435 tumours after treatment.
As shown in Figures 3A and B, concomitant with the induction of
massive necrosis, ZD6126 caused a significant increase in mitosis
and proliferation index 24h after administration. These findings
provided the rationale for administering the cytotoxic drug 24h
after the VDA. Indeed, the combination of ZD6126 with PTX given
24h later resulted in a significant increase in doubling time
compared to each single agent (10.3, 13.8, 32.1, and 41.2 days for
vehicle, ZD6126, PTX, and ZD6126þPTX, respectively, P¼0.02)
and efficacy (%T/C was 39.5 and 23.5 for PTX and ZD6126þPTX,
respectively). Specific growth delay was 2.1 and 3.0 for PTX and
the combination, respectively (Figure 3C).
The potential drawback of this schedule is that pretreatment
with the VDA impairs the functional properties of the tumour
vasculature, hence possibly affecting the distribution of PTX
within the tumour. Since the activity of this class of molecules,
including ZD6126, is rapid and reversible (Micheletti et al, 2003),
scheduling a sufficient time interval after ZD6126 administration
might reasonably avert this possible effect. Figure 4A shows that
administration of PTX 72h after ZD6126 improved the activity
of the combination (%T/C¼5.4) compared to PTX alone
(%T/C¼16.4) or ZD6126 (%T/C¼72.9). In this experiment, despite
the high dose of PTX (40mgkg
 1, close to the maximal tolerated
dose), tumours in all mice treated with PTX alone eventually
regrew, and only in the group receiving the ZD6126/PTX
combination were complete remissions observed (three out of six).
Given their mechanism of action, VDAs – unlike most
angiogenesis inhibitors – are designed for acute treatments. In
this regard, it is worth noting that a single administration of
ZD6126 followed by repeated, weekly administrations of PTX was
sufficient to produce a degree of antineoplastic activity similar to
what was achieved when it was given intermittently in a weekly
schedule with PTX (Figure 4B). As expected, ZD6126 did not exert
any antineoplastic activity by itself under these conditions, but it
was still able to potentiate the activity of PTX, leading to four out
seven complete remissions (Figure 4B).
In all the above experiments, animals showed no evident signs of
toxicity with the combination treatments.
DISCUSSION
Vascular disrupting agents given as single agents have shown poor
antineoplastic activity, whereas their combination with chemo-
therapy has yielded promising responses in preclinical models
(Horsman and Siemann, 2006). Currently, VDAs are being
evaluated primarily in phase II clinical trials in combination with
conventional cytotoxic therapies; combinations with other forms
of therapy are also under investigation (Chaplin et al, 2006).
Timing and sequencing of VDA and chemotherapy administration
are important issues in such treatments. Here, we show that the
antineoplastic efficacy of the combination of a VDA (ZD6126)
with a chemotherapeutic (paclitaxel) depends on the sequence and
schedule of drug administration. We likewise advance some
possible rationales for optimising the combination.
Our previous findings indicated that sequence becomes a crucial
issue when combining VDAs with other tubulin-binding agents.
Paclitaxel protects endothelial cells from the microtubule destabi-
lising effects of ZD6126 by exerting an opposite biological effect
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Figure 2 Effect of paclitaxel (PTX) on ZD6126-induced necrosis
parallels tumour response. (A) MDA-MB-435 cells were xenografted in
nude mice. When the tumours reached approximately 450mg. mice were
treated i.v. with PTX (20mgkg
 1) given 2, 24, 72h, and 1 week prior to
ZD6126 (200mgkg
 1 i.p.). Twenty-four hours after ZD6126 treatment
tumours were excised, sections stained with haematoxylin and eosin (H&E)
and the percentage of necrotic area calculated as described in Materials and
Methods section. Columns indicate the median value. *P¼0.01 compared
to ZD6126 alone (ANOVA followed by Bonferroni/Dunn post hoc test).
(B and C) Mice bearing MDA-MB-435 tumours (approximately 450mg)
were treated with PTX (20mgkg
 1 i.v.) 24h (B)o r7 2 h( C) before
ZD6126 (200mgkg
 1 i.p.). Mice received weekly cycles of treatment for
four courses. n¼6. Black (PTX) and white (ZD6126) arrowheads indicate
treatments. CR¼complete remission (cured mice, remaining disease free
for at least 4 weeks after the end of treatment).
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sthrough microtubule stabilisation, thereby inhibiting the ability
of ZD6126 to induce vessel shutdown and tumour necrosis
(Taraboletti et al, 2005). The antagonism between the two agents
implies that PTX administered before ZD6126 would prevent the
activity of the VDA, thus nullifying the potential of the
combination. Indeed, the present study confirmed previous in
vitro data showing that, regardless of the dose of the chemother-
apeutic, ZD6126 given shortly after PTX did not improve the
antitumour activity of chemotherapy alone. The finding that
tumours pretreated with PTX were made unsusceptible to VDA-
induced necrosis confirmed that the lack of activity of the
combination was likely due to an antagonistic effect of PTX on
the vascular disrupting activity of ZD6126. In keeping with our
previous finding that the protective effect of PTX was reversible
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Figure 3 Antitumour effect of paclitaxel (PTX) given after ZD6126. (A) Mice bearing MDA-MB-435 tumour xenografts were treated with ZD6126
(200mgkg
 1 i.p.) or vehicle as described in the legend to Figure 2. Tumours (n¼5) were removed 24h later, processed and analysed as described in
Materials and Methods section. Necrosis, mitotic index, and proliferation index were evaluated. Symbols indicate values for each tumour (mean of values
from five HPFs/tumours), columns are the median. *P¼0.004 compared to vehicle (Mann–Whitney U-test). (B) Representative images of Ki-67 stained
sections of tumours treated with vehicle (a) or ZD6126 (b). Insets show the whole sagittal area of the tumour (original magnification  10), arrows indicate
the viable area where mitosis and proliferation were analysed. (C) Mice bearing MDA-MB-435 tumours (approximately 450mg) were treated with PTX
(20mgkg
 1 i.v.) 24h after ZD6126 (200mgkg
 1 i.p.). Mice received weekly cycles of treatments for four courses. n¼6–10. Black (PTX) and white
(ZD6126) arrowheads indicate treatments. See for comparison the opposite schedule (namely, PTX given 24h before ZD6126) in Figure 2B.
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 1, i.v.), for four weekly cycles or (B) with a single injection
of ZD6126 (200mgkg
 1, i.p.) followed by four weekly treatments with PTX (40mgkg
 1 i.v.) n¼6–7. Treatments are indicated by black (PTX) and white
(ZD6126) triangles. CR¼complete remission (cured mice, remaining disease free for at least 4 weeks after the end of treatment).
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s(Taraboletti et al, 2005), we found that increasing the time
interval between administration of PTX and VDA resulted
in increased antineoplastic activity of the combination.
This kinetics of the antitumour activity was closely paralleled by
the restored sensitivity of tumours to the vascular disrupting
activity of ZD6126 (as shown by induction of necrosis). The
association between the response to necrosis and the enhanced
antineoplastic activity of the combination indicates that induction
of necrosis is a reliable marker of VDA activity, useful when
designing combination therapies with potentially antagonistic
agents. Imaging techniques, such as MRI or PET, might be suitable
tools to assess the optimal time for VDA delivery after
chemotherapy.
In addition to being a cytotoxic tumour drug, PTX strongly
affects endothelial cells (Belotti et al, 1996), which are the primary
cellular target of ZD6126 in the tumour microenvironment. It is
plausible that optimisation of sequence and timing varies
depending on the mechanism of action and cellular targets of
the drugs in the combinations. We have previously shown that
combinations of VDAs with agents that have the same molecular
activity (i.e., tubulin depolymerisation) have a synergic effect on
endothelial cell morphology and tumour necrosis (Taraboletti
et al, 2005). In the same study, we found that, in vitro, other
chemotherapeutics, such as cisplatin, do not interfere with the
activity of the VDA on vascular cells (Taraboletti et al, 2005).
Nonetheless, sequence and interval between cisplatin and VDA
are relevant in vivo, where pharmacokinetic interactions
between agents may occur (Siemann et al, 2002; Siemann and
Rojiani, 2002a).
Intuitively, it would seem that VDAs should not be given before
chemotherapy, as decreased blood flow and vessel shutdown would
decrease the distribution and uptake of chemotherapeutics
(Chaplin et al, 2006). Nonetheless, our findings indicate that a
superior therapeutic efficacy is obtained when ZD6126 is given
before PTX (compare Figures 2B and 3C). This might indicate that
events elicited by the VDA are relevant to the activity of the
chemotherapy given afterward.
It has been proposed that in a combination therapy, VDAs
would cause necrosis of the inner part of the tumour, whereas
chemotherapy or radiotherapy would target the actively prolifer-
ating cells in the peripheral viable rim. We found that ZD6126
can induce changes in the tumour periphery, as shown by the
significant increase in cell proliferation associated to the viable
tumour tissue (evaluated as the number of mitoses and Ki-67-
positive cells) 24h after its administration. Accordingly, the
administration of PTX 24h after ZD6126 was associated with
an increased antineoplastic activity of the combination, suggesting
that the mechanism of the favourable effect of pretreatment
with ZD6126 might be the increment in the number of
proliferating, PTX-responsive cells in the tumour periphery.
Moreover, a preliminary pharmacokinetic analysis showed that
tumours pretreated with ZD6126 presented an increased ratio
between PTX at the tumour periphery and in the inner part of the
tumour, suggesting that in VDA-treated tumours the chemother-
apeutics concentrate where the tumour is more viable.
The actual target cell in the tumour periphery is still
unidentified. Besides tumour cells, endothelial cells might also
be targeted by the combination, as shown by the increase in
endothelial cell apoptosis induced by the combination of ZD6126
with cisplatin (Goto et al, 2004). A recent study (Shaked et al,
2006) reported that the VDA OXi-4503 caused a rapid (4h)
mobilisation of circulating endothelial progenitor cells (CEP),
which home into the viable rim surrounding the necrotic area,
and, 3 days later, are found to be associated with the tumour
vasculature. The recruitment of CEP by VDA was prevented by
antiangiogenic agents, providing a further rationale for combining
VDA and antiangiogenic compounds (Shaked et al, 2006). ZD6126,
too, mobilises circulating endothelial cells, including CEP
(Beaudry et al, 2005; Beerepoot et al, 2006), and benefits from
the combination with antiangiogenic therapies (Siemann and Shi,
2004). However, PTX itself has antiangiogenic properties (Belotti
et al, 1996), and hence has the potentiality to target CEP (Shaked
et al, 2005). Taken together, these considerations raise the
intriguing possibility that the antineoplastic activity of the
ZD6126/PTX combination is the result of the cytotoxic agent
targeting CEP recruitment to the tumour periphery following VDA
treatment. This hypothesis could also provide a further explana-
tion of our finding that the most favourable antineoplastic effects
were obtained with PTX given after ZD6126. In our study, PTX was
administered at conventional doses/schedule. It would be inter-
esting to investigate whether low-dose metronomic administration
of PTX, reported to act on CEP, would improve the antineoplastic
activity of the combination with the VDA.
Our observation that an enhanced combination schedule was
obtained by increasing the interval between administration of
ZD6126 and of the chemotherapeutic (i.e., 72h) might indicate that
at these conditions a trade-off is achieved between the ‘positive’
effects of VDA on cell proliferation and/or CEP recruitment at
the tumour periphery and the ‘negative’ effects of ZD6126 on the
distribution of PTX within the tumour. The final outcome of
combinations of cytotoxic agents with VDA is therefore the result
of each drug’s effect on tumour cells and on host tissue
compartments (such as tumour blood vessels), and depends on
their pharmacological interactions. All these factors account for
and should be considered when attempting to optimise schedules
and sequence.
Clinical and preclinical studies with ZD6126, as well as with
other VDAs, indicate that these compounds are active at well-
tolerated doses, well below the MTD. The toxicity profile differs
from that observed with cytotoxic chemotherapeutics, indica-
ting that additive toxicity should not be an issue of concern in
combination regimens (Horner et al, 2004; Beerepoot et al,
2006). However, microtubule destabilising VDAs appear to
have some characteristic side effects, particularly cardiovascular
toxicity (Beerepoot et al, 2006; van Heeckeren et al, 2006). In
addition, VDAs are designed for acute rather than chronic
treatments, since their effects in terms of tumour necrosis
are apparent within 24h of treatment. Our finding that significant
antineoplastic activity could be achieved with a single VDA
treatment followed by repeated administrations of PTX in-
dicates that one treatment is enough to compromise tumour
growth, as long as chemotherapy or other forms of treatment
contribute to block tumour progression. The effectiveness of
this combination schedule has important clinical implications,
since some of the possible toxicities of the combined treatment
could be limited.
In conclusion, our study indicates that sequencing is crucial in
determining the antitumour efficacy of chemotherapy with VDA,
and that scheduling of the interval between treatments might be
relevant in determining the magnitude of the response. In the case
of combinations of tubulin-binding compounds, such as ZD6126
and PTX, VDA-induced necrosis and proliferation index can been
used as biological readouts to optimise scheduling of treatments.
The best response was obtained by giving the VDA before the
tubulin-binding cytotoxic agent and by allowing a significant time
interval between the two agents.
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